Evaluation of the effectiveness of subcutaneous pollen weed polen allergens

Background. In European countries, the prevalence of pollen sensitization reaches 30–40%. In Russia pollen allergy ranges from 12,7 to 38 %. In the southern regions the main one is ragweed and weed pollen. The efficacy of the subcutaneous medicinal ragweed allergen has not previously been evaluated...

Full description

Saved in:
Bibliographic Details
Main Authors: L. Yu. Barycheva, L. V. Dushina, S. S. Masalskiy
Format: Article
Language:Russian
Published: Association of Paediatric Allergists and Immunologists of Russia (APAIR) 2023-07-01
Series:Аллергология и Иммунология в Педиатрии
Subjects:
Online Access:https://adair.elpub.ru/jour/article/view/57
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850065260968411136
author L. Yu. Barycheva
L. V. Dushina
S. S. Masalskiy
author_facet L. Yu. Barycheva
L. V. Dushina
S. S. Masalskiy
author_sort L. Yu. Barycheva
collection DOAJ
description Background. In European countries, the prevalence of pollen sensitization reaches 30–40%. In Russia pollen allergy ranges from 12,7 to 38 %. In the southern regions the main one is ragweed and weed pollen. The efficacy of the subcutaneous medicinal ragweed allergen has not previously been evaluated using modern symptom scales.   Methods. Open-label, single-center, placebo-uncontrolled study of 60 patients aged 16–55 years with allergic rhinitis in combination with bronchial asthma and without it. A 2-preseason course of AIT with a subcutaneous allergen of Ambrosia was used for patients with monosensitization and an allergen Ambrosia + Artemisia (for oligosensitized patients) and Ambrosia + a mix of pollen of causal allergen for polysensitized patients. Treatment started 4 months before and stopped 2–4 weeks before the beginning of pollination. The RTSS (Rhinoconjunctivitis total symptom score) scale was used to assess the symptoms, and the DMS (Daily medical score) was used to estimate of medical treatment.   Results. After 1-st season of treatment, there was a rapid decrease in the RTSS to 5,0 [4,0; 9,0] compared to the initial values of 13 [10, 15] points. By the second year, the decline in RTSS amounted to 4,5 [3,0; 4,5] points (p < 0,001), the total effect size by second year was 0,96 (strong effect of the intervention). DMS (before treatment) was 2,0 [2,0; 2,0] points, after the first and second years — 1,0 [1,0; 2,0] points (p = 0,002), with a moderate effect size of 0,67 after the first year; by the second year, the effect size is 0,75 versus baseline (p < 0,01).   Conclusion. Monotherapy with a subcutaneous ragweed allergen or its combination with other allergens show high effectiveness, starting from the first year of therapy. In the second year, the improvement continues, but the dynamics decreases. The study demonstrated a strong size of the effect of medical intervention, which cannot be explained by the placebo effect.
format Article
id doaj-art-0754b257413d4d0cbbcd74be0a60cdef
institution DOAJ
issn 2500-1175
2712-7958
language Russian
publishDate 2023-07-01
publisher Association of Paediatric Allergists and Immunologists of Russia (APAIR)
record_format Article
series Аллергология и Иммунология в Педиатрии
spelling doaj-art-0754b257413d4d0cbbcd74be0a60cdef2025-08-20T02:49:04ZrusAssociation of Paediatric Allergists and Immunologists of Russia (APAIR)Аллергология и Иммунология в Педиатрии2500-11752712-79582023-07-0101162610.53529/2500-1175-2022-1-16-2653Evaluation of the effectiveness of subcutaneous pollen weed polen allergensL. Yu. Barycheva0L. V. Dushina1S. S. Masalskiy2Stavropol State Medical UniversityStavropol State Medical UniversityAssociation Pediatric Allergist and Immunologist RussiaBackground. In European countries, the prevalence of pollen sensitization reaches 30–40%. In Russia pollen allergy ranges from 12,7 to 38 %. In the southern regions the main one is ragweed and weed pollen. The efficacy of the subcutaneous medicinal ragweed allergen has not previously been evaluated using modern symptom scales.   Methods. Open-label, single-center, placebo-uncontrolled study of 60 patients aged 16–55 years with allergic rhinitis in combination with bronchial asthma and without it. A 2-preseason course of AIT with a subcutaneous allergen of Ambrosia was used for patients with monosensitization and an allergen Ambrosia + Artemisia (for oligosensitized patients) and Ambrosia + a mix of pollen of causal allergen for polysensitized patients. Treatment started 4 months before and stopped 2–4 weeks before the beginning of pollination. The RTSS (Rhinoconjunctivitis total symptom score) scale was used to assess the symptoms, and the DMS (Daily medical score) was used to estimate of medical treatment.   Results. After 1-st season of treatment, there was a rapid decrease in the RTSS to 5,0 [4,0; 9,0] compared to the initial values of 13 [10, 15] points. By the second year, the decline in RTSS amounted to 4,5 [3,0; 4,5] points (p < 0,001), the total effect size by second year was 0,96 (strong effect of the intervention). DMS (before treatment) was 2,0 [2,0; 2,0] points, after the first and second years — 1,0 [1,0; 2,0] points (p = 0,002), with a moderate effect size of 0,67 after the first year; by the second year, the effect size is 0,75 versus baseline (p < 0,01).   Conclusion. Monotherapy with a subcutaneous ragweed allergen or its combination with other allergens show high effectiveness, starting from the first year of therapy. In the second year, the improvement continues, but the dynamics decreases. The study demonstrated a strong size of the effect of medical intervention, which cannot be explained by the placebo effect.https://adair.elpub.ru/jour/article/view/57allergic rhinitissubcutaneous allergen-immunotherapyefficacy
spellingShingle L. Yu. Barycheva
L. V. Dushina
S. S. Masalskiy
Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
Аллергология и Иммунология в Педиатрии
allergic rhinitis
subcutaneous allergen-immunotherapy
efficacy
title Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
title_full Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
title_fullStr Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
title_full_unstemmed Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
title_short Evaluation of the effectiveness of subcutaneous pollen weed polen allergens
title_sort evaluation of the effectiveness of subcutaneous pollen weed polen allergens
topic allergic rhinitis
subcutaneous allergen-immunotherapy
efficacy
url https://adair.elpub.ru/jour/article/view/57
work_keys_str_mv AT lyubarycheva evaluationoftheeffectivenessofsubcutaneouspollenweedpolenallergens
AT lvdushina evaluationoftheeffectivenessofsubcutaneouspollenweedpolenallergens
AT ssmasalskiy evaluationoftheeffectivenessofsubcutaneouspollenweedpolenallergens